tesamorelin: the FDA-approved peptide that targets visceral fat

tesamorelin is a synthetic analog of human growth hormone releasing hormone (GHRH) that the FDA approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. it works by amplifying the body's own pulses of growth hormone, which raises IGF-1 into the upper normal range and preferentially reduces visceral fat.

what is tesamorelin?

tesamorelin is a 44-amino-acid peptide identical in sequence to native human GHRH(1-44), with a small chemical modification at one end that protects it from the enzyme that normally breaks down GHRH within minutes. that single change is what makes it a real outpatient drug rather than a research curiosity.

the parent molecule is the full-length 44-amino-acid human GHRH, the hormone the hypothalamus uses to tell the pituitary gland to release growth hormone (GH). native GHRH is destroyed in the bloodstream within about ten minutes by an enzyme called DPP-IV, which makes it impractical as a daily medicine. tesamorelin solves that problem by adding a small trans-3-hexenoyl group to the front of the peptide, physically blocking the spot where DPP-IV would otherwise cleave it. the rest of the molecule is unchanged, so its action at the GHRH receptor is the same as the natural hormone [1].

tesamorelin was developed under the codename TH9507 by Theratechnologies and is marketed in the US under the brand names Egrifta, Egrifta SV, and Egrifta WR. it is the only FDA-approved GHRH analog currently on the US market. its closest relative, sermorelin (a shorter 29-residue GHRH fragment), no longer has an approved branded product.

how does it work?

tesamorelin activates the GHRH receptor on growth-hormone-producing cells in the pituitary, amplifying the natural pulses of GH that the body already releases. those pulses tell the liver to make IGF-1, and the resulting rise in IGF-1 drives a redistribution of fat away from the visceral depot.

the GHRH receptor sits on cells in the anterior pituitary called somatotropes. when tesamorelin docks into it, the receptor turns on a cascade inside the cell (the cAMP-PKA-CREB pathway) that drives both new GH production and the release of GH already stored in tiny granules. crucially, tesamorelin amplifies the body's existing pulse pattern instead of overriding it. the hypothalamus still gates pulses with somatostatin (the off switch), and IGF-1 still feeds back to slow GH release when it climbs too high [2]. the result is a larger natural pulse rather than an artificial flat plateau.

the GH released by each pulse travels through the bloodstream and binds the GH receptor on the liver, which then produces and releases IGF-1. IGF-1 is the molecule that does most of the downstream work, including the lipolytic effect on visceral fat that gives tesamorelin its clinical identity. because the GH pulses are still gated by physiologic feedback, IGF-1 in trials rose into the upper normal range rather than into the supraphysiologic territory associated with growth-hormone excess [3].

what does the evidence show?

tesamorelin's strongest evidence is in HIV-associated lipodystrophy, where two Phase 3 randomized controlled trials and a 52-week safety extension demonstrated a roughly 15 to 18 percent reduction in visceral fat with daily subcutaneous use. a separate program at Massachusetts General Hospital extended the work to hepatic fat in HIV-associated fatty liver disease.

the pivotal study, Falutz and colleagues in the New England Journal of Medicine in 2007, randomized 412 HIV-infected patients with abdominal fat accumulation to tesamorelin or placebo for 26 weeks. visceral adipose tissue measured by CT scan fell by roughly 15.2 percent in the tesamorelin arm and increased modestly in the placebo arm [3]. a pooled analysis of the two Phase 3 trials plus a 26-week safety extension, published by Falutz in the Journal of Clinical Endocrinology & Metabolism in 2010, showed that the response was maintained through 52 weeks of continued therapy and reversed within months of stopping [4]. subcutaneous (peripheral) fat was largely preserved, which is clinically important in a population where peripheral fat loss is already a problem.

a second body of evidence, led by Steven Grinspoon's group at Massachusetts General Hospital, examined hepatic fat. Stanley and colleagues in JAMA in 2014 ran a 12-month single-center RCT (n=50) in HIV-infected adults with central adiposity and reported a roughly 32 percent relative reduction in hepatic fat fraction by magnetic resonance spectroscopy compared with placebo [5]. Stanley's follow-up multicenter trial in Lancet HIV in 2019 extended the finding and reported reduced rates of NAFLD progression on liver biopsy in a substudy of treated patients [6].

outside HIV, the controlled evidence is much thinner. there are no large randomized trials of tesamorelin in non-HIV healthy adults for general body composition or "anti-aging" endpoints. a small program by Baker and colleagues in Archives of Neurology in 2012 reported improved executive function in older adults with mild cognitive impairment after 20 weeks of nightly tesamorelin, but this is hypothesis-generating Phase 2 work and no Phase 3 cognitive program has followed [7]. for everything outside HIV-associated lipodystrophy, the honest framing is: biologically plausible, off-label, and not supported by RCT-grade data at scale.

FDA and regulatory status

the FDA approved tesamorelin in November 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. that is the only approved indication. it is not approved for general body recomposition, age-related changes, non-HIV fatty liver disease, or cognitive endpoints, and the European Medicines Agency did not pursue approval in Europe.

the original Egrifta required refrigerated storage and a two-vial reconstitution workflow. a sucrose-stabilized reformulation, Egrifta SV, simplified storage to room temperature, and a more recent pre-filled pen, Egrifta WR, reduced injection volume and improved convenience. the formulation history is itself a useful lesson in why injectable peptide adherence depends on more than the molecule.

tesamorelin is also on the World Anti-Doping Agency prohibited list under category S2.5 (peptide hormones and growth factors) at all times. any competitive athlete in a WADA-tested sport should be aware that use is banned in and out of competition.

safety profile and side effects

the most common adverse events reported in Phase 3 trials were injection-site reactions, arthralgia, fluid retention, peripheral edema, paresthesia, and headache. a small but real increase in fasting glucose and HbA1c was also documented, which is why glucose monitoring is part of the FDA label.

injection-site reactions (redness, itching, bruising) were the most frequent adverse event in the Phase 3 program and the most common reason for discontinuation [3]. joint aches and fluid retention are mechanistically expected for any GH-axis stimulator and tend to be mild. the glucose signal is the one most worth highlighting: GH antagonizes insulin action, so tesamorelin produces small upward shifts in fasting glucose and HbA1c that are clinically modest in HIV patients but warrant baseline and ongoing monitoring [4].

the FDA label contraindicates tesamorelin in patients with disruption of the hypothalamic-pituitary axis (from hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation, or significant head trauma), in active malignancy, and in pregnancy. the malignancy contraindication is precautionary: chronically elevated IGF-1 is associated in population studies with increased risk of certain cancers, although no cancer signal has emerged in the tesamorelin clinical program through extended follow-up. IGF-1 monitoring during therapy is part of the label and is meant to keep exposure within the age- and sex-adjusted normal range.

the longest formal controlled exposure dataset is the 52-week safety extension of the Phase 3 program. long-term safety beyond a year in healthy non-HIV adults using compounded tesamorelin off-label has not been formally characterized, which is a real gap to teach honestly.

where it fits in peptide therapy

tesamorelin sits in a small family of GHRH-axis tools that includes sermorelin and CJC-1295. it is the only one with FDA approval and Phase 3 evidence, but its approved use is narrow. understanding where it fits requires comparing its pulsatile, feedback-preserving profile against alternatives that either break down faster or signal continuously.

the natural comparison is sermorelin, a shorter GHRH(1-29) fragment that engages the same receptor but breaks down in about twelve minutes. sermorelin has no current FDA-approved branded product and a much thinner modern evidence base, so it survives largely through compounding pharmacies. tesamorelin, with its longer half-life and Phase 3 dataset, is the more rigorously studied member of the GHRH-analog family.

the next comparison is CJC-1295, which exists in two forms. the "no DAC" version is essentially a modified GHRH(1-29) fragment with a half-life similar to tesamorelin's. the "with DAC" version attaches a chemical handle that binds serum albumin and pushes the half-life out to roughly a week. that long half-life produces sustained, non-pulsatile IGF-1 elevation, which is mechanistically very different from tesamorelin's pulse-preserving profile. neither CJC-1295 form is FDA-approved.

a related but mechanistically distinct option is ipamorelin, which acts at the ghrelin receptor (GHSR-1a) rather than the GHRH receptor. the two mechanisms are complementary, which is why tesamorelin and ipamorelin sometimes appear together in community stacks, although no controlled human outcome data exist for that combination. for a broader map of how the GH axis interacts with the GLP-1 family that includes semaglutide and tirzepatide, the underlying biology is covered in our free peptides and your body module.